EPHA #A2MDialogues
A series of online, live, public dialogues putting the spotlight on actionable solutions for access to medicines for decision-makers in Europe
EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Find out more about each event:
The Oslo Medicines Initiative: a new social contract with pharma
A discussion with the WHO European Region and the Norwegian Medicines Agency on the Oslo Medicines Initiative
Negotiating with pharma: lessons from the EU COVID-19 vaccine negotiations
A one-on-one interview with Clemens Auer, Special Envoy for Health, Austrian Ministry of Health.
Sustainable access to effective antibiotics – what should the EU do?
How can we solve the AMR epidemic? What is the role of the EU? What can HERA do?
After COVID-19, what’s next for EU medicines policies?
A one-on-one interview with Professor Guido Rasi, former Executive Director, European Medicines Agency (EMA).
Getting it right: Recommendations for a European BARDA
Will the EU be a wise investor in biomedical R&D or a passive donor? How can we guarantee a public return on public investment?
The Presidencies’ Perspective on the pharmaceutical strategy: Europe’s to-do list on Access to Medicines
Senior representatives of the EU Presidencies of the EU offer their perspectives on the EU’s revision of the Pharmaceutical Strategy.
Pharma & COVID-19: Winners, losers, prospects
Is the affordability debate in Europe changing in light of COVID-19? Who are the big winners and losers?
The EU’s IP strategy: Enabler or barrier?
How do we ensure that IP incentives compensate and reward innovation but do not distort competition? What lessons have we learned on IP in the response to COVID-19?
Unleashing meaningful innovation through regulatory reform
What effect do the shortcomings of current assessment processes have on the quality of innovation? How do we resolve the conundrum of high prices and high uncertainty?
Get the EPHA Newsletter
The best of our activities, right in your inbox!
